Volition Expands Nu.Q® Discover Distribution in Japan with MBL Deal
Event summary
- VolitionRx appointed Medical & Biological Laboratories (MBL) as a non-exclusive distributor of Nu.Q® Discover assays in Japan.
- Nu.Q® Discover serves nearly 100 clients globally, including top pharma and diagnostic companies.
- Volition estimates the Total Accessible Market for relevant companion diagnostics at nearly $1 billion.
- 2025 saw significant revenue growth for Nu.Q® Discover, with similar expectations for 2026.
The big picture
Volition's deal with MBL strengthens its position in Japan's clinical research tools market, particularly in autoimmune diseases. The collaboration aligns with broader trends in pharmaco-epigenetics, where nucleosome-based biomarkers are gaining traction as pharmacodynamic tools. With nearly 100 global clients and a $1 billion TAM, Volition is positioning Nu.Q® Discover as a key player in drug development and diagnostic research.
What we're watching
- Market Expansion
- Whether Volition can sustain revenue growth in 2026 following its 2025 performance.
- Regulatory Pathway
- The pace at which Nu.Q® assays generate data for potential regulatory approval in Japan.
- Pharma Collaboration
- How the MBL partnership will impact adoption of Nu.Q® Discover among Japanese drug developers.
Related topics